2015
DOI: 10.1016/j.clml.2015.07.550
|View full text |Cite
|
Sign up to set email alerts
|

Survival of patients with multiple myeloma in first-line treatment: thalidomide, dexamethasone and zoledronic acid. Report of the National Cancer Institute of México (INCan)

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles